# Special Issue

# Immune Microenvironment and Immunotherapy in Malignant Brain Tumors

## Message from the Guest Editors

Immunotherapy has revolutionized cancer treatment in the last decade by demonstrating the power of the immune system to fight against cancer. Although immunotherapy has brought benefits to patients with many cancer types, patients with brain cancer have not yet experienced these benefits. The brain has a unique tissue immune microenvironment, including the blood–brain barrier, unique resident myeloid cells called microglia and neurons. To improve the efficacy of immunotherapy against brain cancer, we need to better understand the immunobiology of these cancers. Emerging data suggest that the interaction of immune cells not only with other immune cells or cancer cells but also with other cell types, such as neurons and blood vessel cells, significantly impacts brain tumor immunity. There are other factors, such as sex and age, that also could have a significant impact on brain tumor immunity. This Special Issue aims to provide comprehensive information on the current understanding of the immune microenvironment of brain cancer, both primary and metastatic, and potential immunotherapeutic approaches.

## Guest Editors

Dr. Masaki Terabe
National Cancer Institute (NCI), Bethesda, MD, USA
Prof. Dr. Mark R. Gilbert
National Cancer Institute (NCI), Bethesda, MD, USA

## Deadline for manuscript submissions

closed (30 April 2026)

**Cancers**

**an Open Access Journal by MDPI**

**Impact Factor 4.4**
**CiteScore 8.8**
**Indexed in PubMed**

mdpi.com/si/212907

*Cancers*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)